Emrelis
Payments companies reported to CMS as associated with Emrelis. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Emrelis, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Emrelis
These are the largest totals companies reported as associated with Emrelis. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Johnny Chang | Encino, CA | Hematology & Oncology | $40,402.61 |
| Wade Iams | Nashville, TN | Hematology & Oncology | $23,351.68 |
| Jonathan Goldman | Santa Monica, CA | Hematology & Oncology | $18,850.00 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $12,210.90 |
| Mohamed Mohamed | Greensboro, NC | Hematology (Internal Medicine) | $11,820.88 |
| Edgardo Santos | Fort Lauderdale, FL | Hematology & Oncology | $11,625.96 |
| Abhirami Vivekanandarajah | Staten Island, NY | Hematology & Oncology | $11,304.91 |
| Firas Badin | Lexington, KY | Hematology & Oncology | $10,281.34 |
| Eric Nadler | Dallas, TX | Medical Oncology | $9,022.33 |
| Leonid Shunyakov | Bolivar, MO | Medical Oncology | $8,819.29 |
Prescribed Emrelis?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.